PARNF — Parnell Pharmaceuticals Holdings Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $10.74m
- AU$13.17m
Annual income statement for Parnell Pharmaceuticals Holdings, fiscal year end - December 31st, AUD millions except per share, conversion factor applied.
2012 June 30th | 2013 June 30th | 2014 June 30th | 2015 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 6.29 | 9.54 | 7.54 | 13.2 |
| Cost of Revenue | ||||
| Gross Profit | 1.97 | 3.9 | 1.13 | 5.42 |
| Selling / General / Administrative Expenses | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 3.13 | 9.84 | 15.3 | 32.3 |
| Operating Profit | 3.17 | -0.304 | -7.71 | -19.2 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 0.67 | -4.15 | -14.4 | -13.7 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 0.067 | -3.48 | -17.3 | -13.7 |
| Net Income Before Extraordinary Items | ||||
| Net Income | 0.067 | -3.48 | -17.3 | -13.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Dilution Adjustment | ||||
| Diluted Net Income | 0.067 | -3.48 | -17.3 | -13.7 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 0.005 | -0.303 | -2.18 | -1.03 |
| Dividends per Share |